Bibliography
- REID IR, BROWN JP, BURKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl. Med. (2002) 346:653–661.
- BLACK DM, CUMMINGS SR, KARPF DB et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535–1541.
- SCHNITZER T, BONE HG, CREPALDI G et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Ageing (Milano) (2000) 12:1–12.
- ROSSINI M, GATTI D, GIRARDELLOS, BRAGA V, JAMES G, ADAMI S: Effects of two intermittent alendronate regiments in the prevention or treatment of postmenopausal osteoporosis. Bone (2000) 27:119–122.
- PORRAS AG, HOLLAND SD, GERTZ BJ: Pharmacokinetics of alendronate. Clin. Pharmacokinet. (1999) 36:315–328.
- KHAN SA, KANIS JA, VASIKARAN S et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.' Bone Miner. Res. (1997) 12: 1700-1707.
- PASSERI M, BARONI MC, PEDRAZZONI M et al.: Intermittent treatment with intravenous 4-amino-l-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Mineral. (1991) 15:237–247.
- THIE.BAUD D, BURCKHARDT P, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am.Med. (1997) 103: 298–307.
- LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl. Med. (1995) 333:1437–1443.
- HARRIS ST,WATTS NB, GENANT HK et al.: Effects of risendronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA (1999) 282:1344–352.
- REID IR, WATTIE DJ, EVANS MC et al:Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. Clin. Endocrinot Metab. (1994) 79:1595–1599.
- GARNERO P, SHIL WCJ, GINEYTS E, KARPF DB, DELMAS PD: Comparison of new biochemical markers for bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. Clin. Endocrinol Metab. (1994) 79: 1595–1599.
- RAVN P, CLEMMESEN B, RIIS BJ, CHRISTINSEN C: The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of post- menopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone (1996) 19:527–533.
- RECKER RR, STAKKESTAD JA, FELSENBERG D et al: A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PM0): results of a 3-year trial. Osteoporosis mt. (2000) 11\(Suppl. 2):S209. Abstract.
- MITCHELL DY, BARR WH, EUSEBIORA et al.: Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral admin-istration. Pharm. Res. (2001) 18:166–170.
- ORWOLL E, ETTINGER ME, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N Engl. I Med. (2000) 343:604–610.
- ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA (1999) 282:637–645.
- NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl.). Med. (2001) 344:1434–1441.